Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Japan Approves Daratumumab for Relapsed/Refractory Myeloma

October 3rd 2017

The Japanese Ministry of Health, Labor and Welfare has approved the use of daratumumab (Darzalex) for the treatment of adults with relapsed/refractory multiple myeloma.

Brentuximab Vedotin Receives Breakthrough Therapy Designation for Frontline Hodgkin Lymphoma

October 2nd 2017

The FDA has awarded brentuximab vedotin (Adcetris) a breakthrough therapy designation for the first-line treatment of patients with classical Hodgkin lymphoma.

Penn Seeks to Make CAR T-Cell Therapy Work in Solid Tumor Disease

September 30th 2017

Chimeric antigen receptor T-cell therapy for hematological malignancies took a huge step forward this summer with the FDA approval of Novartis

Expert Weighs in on Recent AML Advances

September 28th 2017

Harry Erba, MD, PhD, reflects on the 4 approvals and their effect on the treatment of AML moving forward.

Managing Thromboembolic Events in Pediatric Cancer

September 23rd 2017

Guy Young, MD, discussed the use of anticoagulants in managing thromboembolic events in pediatric cancer.

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL

September 22nd 2017

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

Observation After Diagnosis Viable Strategy for Some Patients With MCL

September 21st 2017

Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.

Dr. Young Discusses Thromboembolic Events in Pediatric Cancer

September 21st 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.

Update Sustains Tisagenlecleucel Activity in Pediatric ALL

September 20th 2017

Tisagenlecleucel (Kymriah) induced a complete remission with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma.

Expert Discusses Strategies for Advancing Pediatric ALL Care

September 20th 2017

The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.

EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis

September 20th 2017

The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia and advanced systemic mastocytosis.

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy

September 20th 2017

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL

September 19th 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

Ibrutinib Highly Active Against MCL in Pooled Analysis

September 19th 2017

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

Venetoclax Combination Improves PFS in Phase III CLL Trial

September 19th 2017

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Lower Dose ATLG Safer, More Effective in Children With Hematologic Malignancies

September 15th 2017

A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

FDA Approves Copanlisib for Follicular Lymphoma

September 14th 2017

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

Early Administration of Cytarabine May Improve Survival in Pediatric ML-DS

September 13th 2017

Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome during the second chemotherapy induction cycle resulted in improved event-free survival and overall survival compared to results observed in previous research studies.